Download PDF
Semin Respir Crit Care Med 2022; 43(02): 280-294
DOI: 10.1055/s-0041-1740605
Review Article

New Antibiotics for Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia

Authors

  • Matteo Bassetti

    1   Infectious Diseases Unit, San Martino Policlinico Hospital—IRCCS for Oncology and Neurosciences, Genoa, Italy
    2   Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy

  • Alessandra Mularoni

    3   Department of Infectious Diseases, Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione (IRCCS), Palermo, Italy

  • Daniele Roberto Giacobbe

    1   Infectious Diseases Unit, San Martino Policlinico Hospital—IRCCS for Oncology and Neurosciences, Genoa, Italy
    2   Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy

  • Nadia Castaldo

    4   Division of Infectious Diseases, Department of Medicine, Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy
    5   Department of Pulmonology, Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy

  • Antonio Vena

    1   Infectious Diseases Unit, San Martino Policlinico Hospital—IRCCS for Oncology and Neurosciences, Genoa, Italy
    2   Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy
Further Information
  Permissions and Reprints

Abstract

Hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) represent one of the most common hospital-acquired infections, carrying a significant morbidity and risk of mortality. Increasing antibiotic resistance among the common bacterial pathogens associated with HAP and VAP, especially Enterobacterales and nonfermenting gram-negative bacteria, has made the choice of empiric treatment of these infections increasingly challenging. Moreover, failure of initial empiric therapy to cover the causative agents associated with HAP and VAP has been associated with worse clinical outcomes. This review provides an overview of antibiotics newly approved or in development for the treatment of HAP and VAP. The approved antibiotics include ceftobiprole, ceftolozane–tazobactam, ceftazidime–avibactam, meropenem–vaborbactam, imipenem–relebactam, and cefiderocol. Their major advantages include their high activity against multidrug-resistant gram-negative pathogens.

Keywords

HAP - VAP - nosocomial pneumonia - new antibiotics - multidrug resistant - Pseudomonas aeruginosa - Klebsiella pneumonia


Publication History

Article published online:
27 January 2022

© 2022. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA